Evidence map›Paper›PMID 42824782›Full record

ReviewFrontiers in immunology2026

Vitamin D and gut microbiota in thyroid diseases: mechanisms and therapeutic potential.

Mei Jiao, Xiaodan Zhai, Zheng Jia, Boshen Gong, Ruofan Shen, Ying Liu, Dianbao Zhang, Zhongyan Shan, Chuyuan Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mei Jiao *Department of Endocrinology and Metabolism, The Institute of Endocrinology, National Health Commission (NHC) Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, Shenyang, China.
Xiaodan Zhai *Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Zheng JiaDepartment of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang, China.
Boshen GongDepartment of Endocrinology and Metabolism, The Institute of Endocrinology, National Health Commission (NHC) Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, Shenyang, China.
Ruofan ShenDepartment of Endocrinology and Metabolism, The Institute of Endocrinology, National Health Commission (NHC) Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, Shenyang, China.
Ying LiuDepartment of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang, China.
Dianbao ZhangDepartment of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission of China, and Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University, Shenyang, China.
Zhongyan ShanDepartment of Endocrinology and Metabolism, The Institute of Endocrinology, National Health Commission (NHC) Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, Shenyang, China.
Chuyuan WangDepartment of Endocrinology and Metabolism, The Institute of Endocrinology, National Health Commission (NHC) Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid diseases have become the most common endocrine disorders globally, including hyperthyroidism, hypothyroidism, thyroid nodules (TN), and thyroid cancer (TC). Traditionally, the pathogenesis was attributed to autoimmune dysfunction, iodine metabolism imbalance, and genetic-environmental interactions. Recently, research suggests that vitamin D deficiency and gut microbiota dysbiosis are prevalent in patients with thyroid disorders, particularly in autoimmune thyroid disease (AITD). Vitamin D, as well as gut microbiota and its metabolites, such as short-chain fatty acids and bile acids, jointly regulate innate and adaptive immunity. They also mitigate intestinal leakage by maintaining intestinal barrier integrity, thereby influencing the development and progression of thyroid diseases. Furthermore, studies confirm the bidirectional interaction between vitamin D and the gut microbiota. Vitamin D supplementation increases the abundance of beneficial bacteria and regulates their metabolites. While beneficial bacteria and their metabolites, such as butyrate and bile acids, promote vitamin D receptor (VDR) expression and enhance vitamin D bioavailability. In this review, we integrate existing current basic and clinical evidence to systematically dissect the individual functions and reciprocal crosstalk of vitamin D and gut microbiota in thyroid diseases. Furthermore, we put forward a combined intervention of vitamin D and gut microbiota, which may serve as a viable therapeutic strategy for thyroid disease.

Indexed as

Gastrointestinal MicrobiomeThyroid DiseasesVitamin DVitamin D DeficiencyAnimalsDysbiosisFatty Acids, VolatileHumansReceptors, CalcitriolFatty Acids, VolatileReceptors, CalcitriolVitamin Dautoimmune thyroiditisgut microbiotashort-chain fatty acidsthyroid-gut axisvitamin D

Identifiers

PMID42824782
PMCPMC13627986

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.